Biotinylated Binding Agents for Drug-Resistant Pathogen Membrane Rupture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing prevalence of antibiotic-resistant bacterial infections, particularly in M. tuberculosis and gram-negative pathogens, poses a significant threat to public health, as traditional antibiotics are insufficient to address these resistant strains.
Innovation Solution
The development of compositions and methods that target multiple surface proteins, lipids, or glycans on pathogens using biotinylated binding agents, followed by the administration of streptavidin crosslinking agents to induce membrane rupture and kill the organisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat bacterial infections, then treatment effectiveness is maintained, but antibiotic resistance develops and spreads
Solution Approach 1:
The patent segments the bacterial cell membrane into multiple target sites by using multiple binding agents that recognize different surface proteins, lipids, or glycans. This segmentation approach ensures that if one target mutates, others remain effective, thereby maintaining treatment reliability while reducing resistance development.
Solution Approach 2:
The invention uses composite binding agents that combine multiple targeting capabilities within a single therapeutic formulation. These composite agents simultaneously attack multiple membrane components, creating a multi-pronged assault that prevents the emergence of resistance while maintaining high treatment effectiveness.
2Object-affected harmful factors
If single pathway/single enzyme/single protein targeting is used, then toxicity is limited and specificity is increased, but drug resistance develops over time
Solution Approach 1:
The patent creates universal binding agents that can target multiple different membrane components (proteins, lipids, glycans) through a single therapeutic platform. This multi-functionality allows the same basic agent to attack various targets, maintaining specificity and low toxicity while preventing long-term resistance through target diversity.
Solution Approach 2:
The invention changes the targeting parameters from single-specificity to multi-specificity by modifying the binding agent repertoire. This parameter change enables simultaneous attack on multiple membrane components, thereby maintaining initial effectiveness and toxicity profiles while eliminating the time-dependent resistance problem.
3Reliability
If multiple surface proteins are targeted simultaneously, then resistance development is reduced, but complexity of the treatment system increases
Solution Approach 1:
The patent merges multiple binding agents with different specificities into a single coordinated therapeutic system. By combining agents that target different membrane components, the system achieves multi-target capability while managing complexity through integrated delivery and coordinated action, rather than requiring separate complex treatments for each target.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively kills drug-resistant pathogens by inducing physical strain on their membranes, reducing the likelihood of resistance development and minimizing harm to host tissues.
Implementation Method 1
Subsequent loading/injection of avidin/streptavidin/neutravidin (or multimeric anti-bet agent). This sequence of process will result in induction of physical strain on the membrane integrity to induce the rupture in the membrane wall
Data Source
AI summary
Disclosed herein is a method for controlled delivery of an agent in a subject that involves administering to the subject a biotinylated cell complex loaded with the agent; and then administering to the subject an effective amount of streptavidin/neutravidin crosslinking agent to crosslink the biotinylated complex. Also disclosed is a method for killing a drug resistant pathogen in a subject that involves administering to the subject biotinylated binding agents that specifically bind one or more antigens on the pathogen, and then administering to the subject an effective amount of streptavidin crosslinking agent to rupture the pathogen.